Drug data last refreshed 5h ago · AI intelligence enriched 3w ago
MANDOL is an injectable small-molecule cephalosporin antibiotic approved by the FDA in 1978 and sponsored by Eli Lilly and Company. The specific indications are not detailed in available data, but cephalosporins are typically used for bacterial infections across multiple organ systems. Mechanism of action involves inhibition of bacterial cell wall synthesis.
As LOE approaches, the brand team will likely transition to lifecycle management and cost-optimization strategies with minimal headcount expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on MANDOL offers exposure to lifecycle management, cost-containment strategies, and competitive positioning in a mature antibiotic market. Career growth is limited due to LOE status, making this role better suited for professionals seeking operational expertise or a stable, lower-intensity work environment.
Worked on MANDOL at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.